As the saga over how to pay for Aduhelm plays out, bio­phar­ma com­pa­nies are now look­ing close­ly at how Bio­gen was able to keep such … ...

The fed­er­al gov­ern­ment has on­ly sent four ship­ments of Mer­ck’s Covid-19 an­tivi­ral mol­nupi­ravir (about 400,000 cours­es in each ship­ment) na­tion­wide, and al­ready HHS is re­port­ing … ...

Melanoma was the first can­cer type for which Bris­tol My­ers Squibb’s Op­di­vo scored an FDA ap­proval. And the phar­ma gi­ant is still try­ing to reach … ...

Alex Gorsky, the CEO whose nine-year tenure at J&J was marred by law­suits over the com­pa­ny’s talc ba­by pow­der and opi­oids, will ...

When ac­tor Bel­lamy Young was grow­ing up, her fa­ther suf­fered from a brain dis­or­der called he­pat­ic en­cephalopa­thy (HE) caused by cir­rho­sis of the liv­er. … ...

SAB Bio­ther­a­peu­tics said Thurs­day the US fed­er­al gov­ern­ment is pro­vid­ing it with an ad­di­tion­al $60.5 mil­lion, and more than $200 mil­lion in to­tal, to ad­vance … ...

PARIS — Last fall De­ci­phera suf­fered through a dis­as­trous set­back $DCPH with its lead drug, Qin­lock, which had been ap­proved as a fourth-line ther ...

Just a few days af­ter pric­ing a $150 mil­lion pub­lic of­fer­ing, Io­vance has now closed with 15% more raised, thanks to … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

In a sur­prise U-turn, the Biden ad­min­is­tra­tion said Wednes­day that it will sup­port a pro­pos­al at the World Trade Or­ga­ni­za­tion to tem­porar­i­ly waive in­tel­lec­tu­al prop­er­ty … ...

A bill that re­quires the Di­rec­tor of Na­tion­al In­tel­li­gence to de­clas­si­fy new in­for­ma­tion on the ori­gins of Covid-19 passed the House … ...

Months af­ter earn­ing its first ap­proval, Idor­sia is back with a Phase III win for a dif­fer­ent, J&J-part­nered drug.